Zentek CEO Greg Fenton on Revolutionizing Graphite Purity and Commercializing Breakthrough Filtration Technology

written by InvestorNews | March 19, 2025

March 19, 2025 – Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN) is poised to revolutionize the graphite and critical mineral sectors, underscored by CEO Greg Fenton's statement: "It's probably the most exciting time in the history of Zentek." In a recent interview with InvestorNews host Tracy Hughes, Fenton highlighted the Albany graphite deposit as uniquely positioned to address critical mineral demands. Located in central Ontario, Albany has demonstrated exceptional purity, achieving "five nines" (99.999+%) purity in graphite through an environmentally friendly, two-step thermal process, bypassing intermediate hydrometallurgical stages. According to Fenton, this method positions Albany graphite competitively for "the highest value markets," notably nuclear, military, and lithium-ion battery applications, emphasizing the deposit's strategic significance, especially with growing interest from the United States, where Zentek recently engaged in discussions with Congress regarding the resource's national security importance.

The intersection of technology and critical minerals further differentiates Zentek. CEO Greg Fenton noted that Zentek's proprietary ZenGUARD™ antimicrobial technology, applied to HVAC filters, is nearing commercialization, with initial revenues anticipated by the end of March 2025. "We announced that we will

be commercializing by the end of the first quarter to early adopters," confirmed Fenton, emphasizing this milestone as a pivotal achievement for Zentek. Recently completed shelf-life efficacy testing demonstrated that ZenGUARD™ Enhanced Air Filters maintain consistent viral filtration efficiency after 20 months, solidifying the company's position in the medical device market. Zentek's ZenGUARD™ filters will soon enter commercialization under a Class I medical device establishment license, fulfilling a critical demand for safer and more efficient air filtration systems.

Looking ahead, Zentek is not only advancing its graphite and filtration technologies but also exploring new opportunities in biotechnology. Fenton indicated upcoming developments in Zentek's biotech division, specifically its therapeutic solution for avian influenza (H5N1), supported by a grant from Innovation Solutions Canada. He concluded optimistically, "We're very, very excited about where we are as a company," highlighting Zentek's strategic alignment with burgeoning interest in critical minerals, advanced filtration, and healthcare innovation, solidifying the company's position as a leader at the intersection of technology and resources.

To access the complete interview, click here

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters. Zentek’s ZenGUARD™ production facility is in Guelph, Ontario.

Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.